Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
1.840
+0.050 (2.79%)
At close: Apr 28, 2026, 4:00 PM EDT
1.830
-0.010 (-0.54%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Compass Therapeutics stock have an average target of 14.57, with a low estimate of 7.00 and a high estimate of 30. The average target predicts an increase of 691.85% from the current stock price of 1.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Compass Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 4 | 4 |
| Buy | 3 | 5 | 6 | 6 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 10 | 11 | 11 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $7 | Strong Buy | Maintains | $13 → $7 | +280.43% | Apr 28, 2026 |
| Citizens | Citizens | Buy Reiterates $10 | Buy | Reiterates | $10 | +443.48% | Apr 28, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +1,204.35% | Apr 27, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,530.43% | Apr 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +552.17% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
6.02M
Revenue Next Year
62.22M
from 6.02M
Increased by 934.41%
EPS This Year
-0.41
from -0.42
EPS Next Year
-0.50
from -0.41
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 41.3M | 179.4M | ||||||
| Avg | 6.0M | 62.2M | ||||||
| Low | n/a | 12.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 2,881.7% | ||||||
| Avg | - | 934.4% | ||||||
| Low | - | 108.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.18 | -0.09 | ||||||
| Avg | -0.41 | -0.50 | ||||||
| Low | -0.61 | -1.43 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.